Inozyme Pharma Advances Treatment for ABCC6 Deficiency with INZ-701

Inozyme Pharma's Commitment to Addressing ABCC6 Deficiency and Related Disorders

Understanding ABCC6 Deficiency

Recent findings indicate that individuals with a single mutated copy of the ABCC6 gene (monoallelic ABCC6 Deficiency) can experience severe symptoms, suggesting a higher global prevalence than previously estimated, which was based only on biallelic cases. Currently, there are no approved treatments for ABCC6 Deficiency, highlighting a significant unmet medical need.

About Inozyme Pharma

Inozyme Pharma is a clinical-stage biopharmaceutical company at the forefront of developing novel therapeutics for rare diseases affecting bone health and vascular function. The company specializes in the PPi-Adenosine Pathway, where the ENPP1 enzyme generates inorganic pyrophosphate (PPi) and adenosine, crucial for regulating mineralization and controlling intimal proliferation within blood vessels. Disruptions in this pathway can lead to severe musculoskeletal, cardiovascular, and neurological conditions, including ENPP1 Deficiency, ABCC6 Deficiency, calciphylaxis, and ossification of the posterior longitudinal ligament (OPLL).

INZ-701: A Promising Therapeutic Candidate

Inozyme Pharma's lead candidate, INZ-701, is an ENPP1 Fc fusion protein enzyme replacement therapy (ERT) designed to increase PPi and adenosine levels. This innovative treatment is currently in clinical development for ENPP1 Deficiency, ABCC6 Deficiency, and calciphylaxis. By targeting the PPi-Adenosine Pathway, INZ-701 aims to correct pathological mineralization and intimal proliferation, potentially reducing the morbidity and mortality associated with these debilitating diseases.

For more information, please visit Inozyme Pharma's website or follow them on LinkedIn, X, and Facebook.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements, including those related to the benefits of INZ-701. These statements are based on current expectations and are subject to risks and uncertainties, including the ability to conduct and enroll patients in clinical trials, obtain regulatory approvals, and manage financial resources. For a detailed discussion of these risks, please refer to Inozyme Pharma's most recent SEC filings.

Contacts

Investors:
Inozyme Pharma
Stefan Riley, Senior Director of IR and Corporate Communications
(857) 330-8871
Stefan.riley@inozyme.com

Media:
Biongage Communications
Todd Cooper
(617) 840-1637
Todd@biongage.com